Mandelblatt J, Gopaul I, Wistreich M
JAMA. 1986 Jul 18;256(3):367-71.
Mortality from cervical cancer is decreasing in countries where aggressive Papanicolaou smear screening programs are in place. However, elderly women are likely to be lifelong nonusers or underusers of Papanicolaou screening, and mortality has not declined for older women. Many studies have noted that nonparticipants in Papanicolaou screening have a 2.7 to four times greater incidence of cervical cancer when they are screened compared with women who have been screened at least once. Gynecological screening was offered to 1542 elderly women in a primary care setting; 75% of the women had not had regular prior screening and 25% had never been screened. Half of these women chose to participate in our screening program. An overall prevalence rate of 13.5 per 1000 abnormal Papanicolaou smears (95% confidence interval, 5.6 to 21.4) was noted in the group. Age, race, prior screening history, and abnormal gynecological symptoms failed to predict the women who would have abnormal Papanicolaou smears. Our results suggest that cervical cancer screening should continue beyond 65 years of age if women have not received regular prior screening.
在实施积极的巴氏涂片筛查计划的国家,宫颈癌死亡率正在下降。然而,老年女性可能一直未进行巴氏涂片筛查或筛查不足,老年女性的死亡率并未下降。许多研究指出,未参与巴氏涂片筛查的女性在接受筛查时患宫颈癌的几率比至少接受过一次筛查的女性高2.7至4倍。在初级保健机构中,对1542名老年女性进行了妇科筛查;75%的女性此前未进行过定期筛查,25%的女性从未接受过筛查。这些女性中有一半选择参加我们的筛查计划。该组中每1000例巴氏涂片异常的总体患病率为13.5(95%置信区间为5.6至21.4)。年龄、种族、既往筛查史和妇科异常症状均无法预测哪些女性会出现巴氏涂片异常。我们的结果表明,如果女性此前未接受过定期筛查,65岁以上仍应继续进行宫颈癌筛查。